Type I interferon in Lupus from Genetic Risk to Treatment Approach

Dates and Times

Start: 4/23/2025 8:00 AM
End: 4/23/2025 9:00 AM

Objectives

Understand the role of type I interferon in lupus pathogenesis.

Learn about new treatments for lupus that target the interferon pathway.

Understand how infectious diseases have likely shaped the genetics of our interferon system.

Speakers

Accreditation

The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits ^™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.